Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma

Alex B. Blair, Lei Zheng

Research output: Contribution to journalReview articlepeer-review


The complex interaction between the immune system, the tumor and the microenvironment in pancreatic ductal adenocarcinoma (PDA) leads to the resistance of PDA to immunotherapy. To overcome this resistance, combination immunotherapy is being proposed. However, rational combinations that target multiple aspects of the complex anti-tumor immune response are warranted. Novel clinical trials will investigate and optimize the combination immunotherapy for PDA.

Original languageEnglish (US)
Article number31
JournalChinese Clinical Oncology
Issue number3
StatePublished - Jun 1 2017


  • Checkpoint inhibitors
  • Combination immunotherapy
  • GVAX
  • Immunotherapy
  • Pancreatic cancer
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this